Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CXCL8 | P10145 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.40 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10338678 | 0.85 | TSHR (0.41) | L3MBTL1TSHRCXCL8ALDH1A1KMT2A | |
| SCHEMBL3342292 | 0.85 | EPHX1 (0.53) | EPHX1L3MBTL1HPGDLMNAGAA | |
| SCHEMBL6006352 | 0.85 | HTR1A (0.46) | L3MBTL1TSHRCXCL8 | |
| SCHEMBL47951 | 0.83 | L3MBTL1 (0.48) | L3MBTL1HPGDTSHRALDH1A1MEN1 | |
| SCHEMBL6668242 | 0.82 | KMT2A (0.59) | EPHX1LMNAGAATSHRMEN1 | |
| SCHEMBL9616117 | 0.82 | KDM4E (0.44) | L3MBTL1TSHRCXCL8ALDH1A1PTGDR2 | |
| SCHEMBL3628841 | 0.82 | PTGS2 (0.53) | EPHX1HPGDLMNATSHRALDH1A1 | |
| SCHEMBL611228 | 0.82 | CXCL8 (0.42) | EPHX1L3MBTL1HPGDTSHRCXCL8 | |
| SCHEMBL4787649 | 0.82 | EPHX1 (0.50) | EPHX1L3MBTL1HPGDLMNATSHR | |
| SCHEMBL8762969 | 0.82 | EPHX1 (0.50) | EPHX1L3MBTL1HPGDLMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10570161-B2 | Unique dual-action therapeutics | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2020-02-25 | — | — | US | disclosed |
| US-20170143836-A1 | UNIQUE DUAL-ACTION THERAPEUTICS | LEHIGH UNIVERSITY | 2017-05-25 | — | — | US | disclosed |
| US-20120010168-A1 | Unique Dual-Action Therapeutics | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2012-01-12 | — | — | US | disclosed |
| WO-2010051044-A1 | UNIQUE DUAL-ACTION THERAPEUTICS | UNIVERSITY OF MEDICINE AND DENTISTRY (US) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010168-A1 | Unique Dual-Action Therapeutics | ACHE, PDE1A, PDE1C | EPHX1 227/4885L3MBTL1 4648/4885HPGD 233/4885 |
| US-20170143836-A1 | UNIQUE DUAL-ACTION THERAPEUTICS | ACHE, PDE1A, PDE1C | EPHX1 227/4885L3MBTL1 4648/4885HPGD 233/4885 |
| US-10570161-B2 | Unique dual-action therapeutics | ACHE, PDE1A, PDE1C | EPHX1 167/4885L3MBTL1 4614/4885HPGD 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.